Crystalline forms of evenamide
AssigneeNewron Pharmaceuticals S.p.A.
InventorsChristoph Imboden, Andrea Castellin
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel crystalline forms of evenamide salts, in particular forms I and II, their use a process for their preparation, and a pharmaceutical composition containing said novel crystalline forms.
Claims23
A crystalline form of evenamide salt designated as form I, having an XRPD spectrum with the characteristic peaks, measured using Cu Kα radiation (λ=1.54 Å), falling at about 12.1;
- 13.4;
- 16.2;
- 16.7;
- 18.2;
- 18.7;
- 19.4;
- 21.7;
- 22.4;
- 22.8;
- 23.3;
- 23.7;
- 24.2;
- 24.4;
- 25.4;
- 26.0;
- 26.6±0.2° in 2θ.
A crystalline form of evenamide salt designated as form II, having an XRPD spectrum with the characteristic peaks, measured using Cu Kα radiation (λ=1.54 Å), falling at about 12.7;
- 17.7;
- 20.0;
- 20.4;
- 20.7±0.2° in 2θ.
A crystalline form of evenamide salt which is selected from a salt exhibiting a predominant endothermic peak:
- at about 119° C.;
- at about 132.6° C.;
- at about 105.6° C.;
- at about 118.3° C.;
- at about 114.6° C.;
- at about 154.8° C.;
- at about 140.7° C.;
- at about 101.2° C.;
- at about 85.8° C.;
- at about 91.4° C.;
- at about 147.9° C.;
- at about 197.8° C.;
- at about 120.0° C.;
- at about 161.8° C.;
- at about 139.5° C.;
- at about 184.5° C.;
- at about 107.0° C.;
- at about 198.3°° C.;
- at about 96.6° C.;
- at about 150.1° C.;
- at about 129.0° C.;
- or
- at about 105.0° C.
-15. (canceled)
(canceled)
Dependencies are inferred from the claim text.